Targeted or combination therapy based on HSP60 inhibitors may be a promising avenue for enhancing the efficacy of cancer treatment since HSP60 inhibitors impact the molecular chaperone activity or post-translational modification of HSP60 [8]. This evidence concerns the gene HSPD1 and cancer.